CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line treatment (EOT), as defined by positive measurable residual disease detected by Foresight CLARITY (PhasED-seq). Participants will initially be pre-screened for MRD status after first line treatment (1L) with chemoimmunotherapy including a CD20 monoclonal antibody and anthracycline.

NCT Number	NCT07443137
Lead Sponsor	Stanford University Collaborators: Novartis
Conditions	Large-cell Lymphoma
Enrollment	20 participants
Start Date	2026-07
Primary Completion	2028-08 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-04